Piramal Pharma Q1 FY27: Revenue up 17%, loss narrows

Overview of Piramal Pharma’s Q1 FY27 results

Piramal Pharma Ltd. reported a narrower consolidated net loss for the first quarter of FY27, supported by double-digit growth in revenue and a sharp improvement in operating profitability. The company disclosed the performance for the quarter ended June 30, 2026, in its quarterly earnings filing. The key takeaway was a strong improvement in EBITDA and EBITDA margin versus the year-ago period, even as the company remained in a net loss position on a consolidated basis.

The quarter’s numbers matter because they show a meaningful change in operating leverage, with profitability improving faster than revenue. The filing also provides standalone revenue figures, giving investors another lens to track business momentum. Separately, the company had indicated that its board would meet on July 29, 2026, to consider unaudited standalone and consolidated results for Q1 FY27.

Consolidated profit and loss: net loss narrows

On a consolidated basis, Piramal Pharma posted a net loss of ₹69.4 crore for Q1 FY27. This compared with a net loss of ₹81.7 crore in the corresponding quarter last year. The year-on-year reduction in loss was quantified in the article as about 15.06%.

While the company stayed in the red, the improvement is consistent with the stronger operating performance reported for the quarter. The narrowing of losses also came alongside a higher EBITDA margin, indicating that cost and operating efficiency trends improved versus the prior-year quarter.

Revenue growth: operations rise 17.4% year-on-year

Revenue from operations increased 17.4% year-on-year to ₹2,270 crore in Q1 FY27. In the year-ago quarter, revenue from operations was ₹1,934 crore. The gap between these two numbers highlights the scale of growth achieved during the quarter.

The article positions revenue growth as a core support for the quarter’s performance, alongside the rise in margins. With revenues moving higher, the ability to convert incremental revenue into operating profit became a key driver of the EBITDA expansion.

Operating performance: EBITDA jumps 82.9%, margin expands

EBITDA rose sharply to ₹195 crore in Q1 FY27, up 82.9% from ₹107 crore in the year-ago period. This increase was much faster than the pace of revenue growth, resulting in a higher EBITDA margin.

EBITDA margin expanded to 8.6% in Q1 FY27 from 5.5% in the corresponding quarter last year. The filing linked the improvement to stronger operating leverage and improved profitability. The margin expansion is a central element of the quarter’s story because it explains why operating profit improved substantially even though the company reported a net loss.

Standalone revenue: growth of about 16% YoY

Alongside consolidated numbers, the article also reported standalone revenue from operations for the quarter. Standalone revenue came in at ₹1,124.95 crore, up from ₹969.88 crore in the corresponding quarter last year. The year-on-year growth was stated as 15.99%.

Standalone figures can differ from consolidated results due to the presence of subsidiaries and other consolidation effects. Still, the standalone revenue growth rate broadly aligns with the narrative of double-digit growth during the quarter.

Context from the previous quarter and balance sheet detail

The article included a quick snapshot that referenced the previous quarter’s figures. Previous quarter revenue was stated as ₹2,752 crore, and the previous quarter PAT was shown as (₹9 crore). The previous quarter EBITDA margin was listed as 18%.

It also reported net debt for the latest quarter at ₹4,296 crore. These data points provide context on the company’s recent trendlines and financial position, although the quarter being discussed in detail is the one ended June 30, 2026.

Currency and acquisition factors mentioned in the preview

The text also referenced factors expected to support Q1 FY27 revenue growth, including currency movement and an acquisition contribution. It stated that revenue growth was expected to benefit from a favourable INR depreciation of approximately 12% to 14% against the USD compared to Q1 FY26.

It further cited the first full quarter contribution from the Kenalog acquisition, targeting annualised revenues of US$10 million to US$10 million. These points were presented as part of the expectations framework in the article, alongside the reported quarterly performance metrics.

Stock and estimate references included in the article

The article also mentioned Piramal Pharma’s CMP at ₹168. It cited an estimated 12-month target range of ₹160 to ₹182 and provided a Q1 FY27 estimated revenue range of ₹1,854 crore to ₹2,133 crore, along with a PAT estimate range of (₹36 crore to ₹46 crore).

These figures were included as part of a preview and estimate framework and sit alongside the reported results. Investors typically compare such ranges with actual numbers once results are declared and filings are available.

Key numbers at a glance

Why the quarter matters for tracking performance

The quarter’s key signal is the combination of revenue growth and a sharp improvement in EBITDA and margins. Revenue rose 17.4% year-on-year, but EBITDA rose 82.9%, indicating that operating leverage improved materially versus the prior-year quarter. The EBITDA margin expansion from 5.5% to 8.6% reinforces that trend.

At the same time, the company still reported a consolidated net loss, even though the loss narrowed. For investors and sector watchers, this keeps the focus on whether operating gains continue to translate into bottom-line improvements over coming quarters.

Conclusion

Piramal Pharma’s Q1 FY27 filing showed revenue from operations of ₹2,270 crore, EBITDA of ₹195 crore, and an EBITDA margin of 8.6%, alongside a consolidated net loss of ₹69.4 crore that narrowed year-on-year. Standalone revenue from operations rose to ₹1,124.95 crore, highlighting growth on that measure as well. The company had also indicated a board meeting on July 29, 2026, to consider unaudited standalone and consolidated results, keeping attention on formal approvals and disclosures tied to the quarter’s financial reporting cycle.